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Objective: The hand-sewn anastomosis is the “gold standard” for performing cor-
onary artery bypass grafts. However, performing a hand-sewn anastomosis is more
demanding and time-consuming when used in less invasive approaches such as
small access, totally endoscopic or beating heart surgery. In conjunction with
attempts to reduce the surgical trauma of coronary artery bypass grafts by using
these less invasive approaches, alternative methods for constructing distal anasto-
moses should be explored. These data report on predischarge angiographic findings
and 30-day clinical follow up of patients who have received a new distal anasto-
motic device.
Methods: In a multicenter trial, 32 patients (mean age: 65  9 years; 85% men)
requiring multivessel coronary artery bypass surgery had 1 of the anastomoses
performed using a novel anastomotic technology. The Magnetic Vascular Positioner
System was used in 1 of the bypass grafts and the other bypasses were completed
by conventional hand-sewn technique. The Magnetic Vascular Positioner System
consists of 4 magnetic, gold-plated implants and 2 delivery devices that facilitate the
creation of a functional end-to-side anastomosis. A predischarge angiogram was
performed to evaluate graft patency.
Results: There were no device-related major adverse events. The application of the
Magnetic Vascular Positioner device was successful in 32 of 41 cases (78%). Nine
patients were intended for treatment but did not receive the Magnetic Vascular
Positioner System. In 5 of the cases the coronary artery was too small; 1 case had
a posterior wall plaque in the target artery; and 3 patients had a nonhemostatic
anastomosis after coupling of the port and were subsequently converted to hand-
sewn anastomoses. The median total Magnetic Vascular Positioner anastomotic
time was 137 seconds with a range from 65 to 370 seconds. Overall patency rate of
the Magnetic Vascular Positioner anastomosis was 93.5% versus 91.7% (P  not
significant) in hand-sewn grafts. One patient (3.1%) died due to low cardiac output
but had patent grafts at autopsy. One myocardial infarction (3.1%) occurred the day
after a percutaneous transluminal coronary angioplasty of a hand-sewn graft. One
prolonged mechanical ventilation (3.1%) was required because of pneumonia and
adult respiratory distress syndrome.
Conclusions: Magnetic vascular coupling in coronary surgery is safe and effective
and has acceptable early patency rates. This new technique may facilitate beating
heart and minimally invasive coronary artery bypass grafts.
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The hand-sewn anastomosis is the “gold stan-dard” in coronary artery bypass grafting(CABG). To reduce the surgical trauma, lessinvasive approaches (MIDCAB) and beatingheart surgery (OPCAB) have been initiated.Because conventional hand-sewn techniques
are slow and cumbersome under conditions of limited ac-
cess, particularly so on the beating heart, alternative meth-
ods for constructing the distal anastomosis are being devel-
oped. Video-assisted, closed-chest CABG may further
complicate the procedure and prolong occlusion time and
the ischemic period while tedious anastomoses are being
performed.1 Numerous attempts have been made to use
micromechanical bonding to perform CABG. Scheltes and
colleagues2 describe 51 devices for the distal anastomosis,
categorized into 4 groups: staples, clips, mounting systems,
and intraluminal stent structures.3 Other sutureless anasto-
motic concepts such as fibrin and bioglue anastomoses have
also been described.4,5 Most of the distal anastomotic de-
vices have only been tested in the laboratory and have not
found their way into clinical practice. Only a few distal
anastomotic devices have been tested clinically utilizing
different technical approaches.6-8
One goal in coronary surgery is to achieve complete
revascularization through a small incision preferably on the
beating heart. Currently, few centers are performing these
technically demanding and still developmental proce-
dures.9,10 Widespread adoption is unlikely without signifi-
cant advances in technology such as stabilizers and easily
deployable and reliable anastomotic devices.
This multicenter clinical trial investigated the safety and
efficacy of a novel anastomotic device, the Magnetic Vas-
cular Positioner (MVP) System (Ventrica, Inc, Fremont,
Calif) to facilitate the construction of a distal coronary
anastomosis.
Methods
From July 23 to October 16, 2001, thirty-two patients received the
MVP device in a multicenter trial conducted at Hannover Medical
School, Leipzig Heart Center, and the University Clinic of Frank-
furt. The protocol was approved by each center’s ethics committee
in compliance with the Declaration of Helsinki.11 Patient demo-
graphics and preimplant characteristics are summarized in Table 1.
The MVP study inclusion criteria included subjects with multives-
sel coronary disease, with the target coronary artery having an
upstream stenosis of 80%, and free of plaque or calcification at
the anastomotic site. Subjects excluded from the study had a left
ventricular ejection fraction 30% or a contraindication to either
aspirin or clopidogrel and those patients undergoing emergent
CABG, redo CABG, or requiring additional noncoronary proce-
dures. One anastomosis in each patient was performed by means of
a magnetic vascular coupling device as described below. All other
anastomoses were hand-sewn. Left internal thoracic arteries (LI-
TAs) and saphenous vein grafts (SVGs) were used with the MVP
device.
Preoperative and Postoperative Anticoagulation
Regimen
Twelve to 24 hours preoperatively patients received a single load-
ing dose of 500 mg aspirin and 300 mg clopidogrel (Plavix; Sanofi
Synthelabo GmbH, Berlin, Germany). On the day of operation no
concomitant anticoagulation therapy was administered except for
heparin for cardiopulmonary bypass. On the first postoperative day
patients started 75 mg of clopidogrel daily for 12 weeks and a
chronic course of 100 mg of aspirin daily.
Operative Procedure
Standard techniques for induction and maintenance of anesthesia
during the procedure were used in all 3 centers. Twenty-six pa-
tients were operated on using standard cardiopulmonary bypass
techniques and cardiac arrest. Heparin (350 U/kg) was adminis-
tered initially; activated clotting time levels were thereafter tar-
geted to remain above 400 seconds. Six patients had an off-pump
beating heart procedure with mechanical stabilization using the
Axius stabilization system (Guidant, Santa Clara, Calif). Aprotinin
TABLE 1. Patient demographic data and preimplant char-
acteristics
n  32 MVP Study
Age (y), range 65  9 (41-80)
Gender
Male 27 84.8%
Female 5 15.2%
CCS class (angina status)
I 4 12.5%
II 17 53.1%
III 9 28.1%
IV 2 6.3%
NYHA class 1 n/d
I 3 9.4%
II 18 56.3%
III 9 28.1%
IV 1 3.1%
Comorbidities
Hypertension 23 71.9%
Diabetes mellitus 10 31.3%
Hypercholesterolemia 15 46.9%
Smoker 15 46.9%
Family history of coronary disease 10 31.3%
Renal failure 2 6.3%
Chronic obstructive pulmonary disease 4 12.5%
Peripheral vascular disease 8 25%
Cerebrovascular disease 5 15.6%
Other major morbidity 7 21.9%
Hyperlipoproteinemia (n  2)
Hyperuricemia
Obesity (BMI  30)
Hyponatremia
Pacemaker
Pulmonary embolis
CCS, Canadian Cardiovascular Society angina classification; NYHA, New
York Heart Association classification; n/d  no data; BMI, body mass
index; MVP, Magnetic Vascular Positioner. Results are mean  standard
deviation.
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(Trasylol; Bayer, Leverkusen, Germany) or epsilon amino capron
acid was not routinely used.
Target Vessel and Intention to Treat
The target vessel and site of anastomosis was chosen intraopera-
tively based on the surgeons’ personal subjective decision. The
anastomotic site was required to be free of plaque and to have a
minimum intraluminal diameter of 2.0 mm. Intention to treat was
defined as intraoperative decision to attempt to perform an MVP
anastomosis.
Description of Device
The MVP System consists of 4 magnetic implants and 2 delivery
systems for completion of an anastomosis. A pair of magnetic,
elliptically shaped, gold-plated implants with an open area of 8.1
mm2 is placed into a 5.0 mm longitudinal incision near the end of
a ligated graft vessel to create an anastomotic port (Figure 1). One
magnetic implant lies just within the graft lumen at the incisional
site (intravascular magnetic implant). The other is held in place on
the external surface of the vessel by mutual magnetic attraction,
precisely above the first implant (extravascular magnetic implant).
The implants hold the elliptically shaped anastomotic port open.
The second pair of magnetic implants forms an identical port in the
coronary artery and is introduced in the same manner as was done
at the graft port. The 2 ports formed by the magnetic implant pairs
are then brought together, allowing the magnetic attraction of the
2 pairs to maintain apposition and form a reliable side-to-side
anastomosis (functional end-to-side). The distal end of the bypass
was either clipped or tied off. In addition, 2 to 4 tacking sutures
were placed according to the protocol to secure the position of the
MVP graft.
Angiographic and 30-Day Postoperative Clinical
Evaluation
Patency was evaluated angiographically prior to hospital dis-
charge. Bypass grafts were graded as either patent or not patent
based on evidence of flow going from the graft into the target
vessel. The 30-day clinical follow-up included a physical exami-
nation, an assessment of angina status, and a determination of the
presence or absence of a major adverse cardiac events: death,
myocardial infarction, or reintervention.
Statistical Analysis
Data are expressed as mean standard deviation. In addition, 95%
confidence intervals were calculated to facilitate comparison of
patency rates between groups. After testing for normal distribution
the paired Student t test was used for intragroup comparison of the
Canadian Cardiovascular Society (CCS) angina class; P .05 was
considered significant.
Results
Forty-one patients were enrolled in the study. Of these, 32
patients (78%) received the device and were followed. In
Figure 1. The Magnetic Vascular Positioner System consists of 4 magnetic implants and 2 delivery systems for
completion of an anastomosis. Illustrations show the stepwise completion of an MVP anastomosis. See text for
detailed information.
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the 32 patients undergoing multivessel coronary revascular-
ization, a total of 32 MVP and 74 hand-sewn anastomoses
were performed. Clinical data for the MVP anastomoses are
summarized in Table 2. A representative postoperative an-
giogram of an MVP LITA graft is shown in Figure 2. There
were no intra- or postoperative adverse events related to the
use of the MVP system.
In 3 patients the MVP anastomosis had to be redone due
to excessive tissue within the lumen of the anastomotic area
(graft or coronary port). The study design targeted 10%
tissue in the orifice of the MVP port on either the coronary
artery or graft. In all 3 cases the magnet pairs could be easily
removed without any apparent trauma to the target vessels.
In all of these cases, the MVP was redeployed with a
successful anastomosis being created and all were patent as
demonstrated in the predischarge angiogram.
Major Adverse Events
There was 1 death (3.1%) in this series, unrelated to the
device. The patient had a hand-sewn LITA graft to the left
anterior descending artery (LAD), a hand-sewn SVG to the
second obtuse marginal branch (OM), and an MVP SVG to
the intermediate branch. After an initially uneventful oper-
ation the patient’s electrocardiogram (ECG) showed isch-
emia of the anterior wall and septum. Cardiac enzymes were
within normal limits. The patient was reexplored and no
graft occlusions were found. The cause of death has been
classified as low cardiac output syndrome. At autopsy all
grafts were confirmed as patent. No histological studies of
the MVP device were performed, as the device was not
explanted at the time of autopsy.
One patient (3.1%) suffered a myocardial infarction with
positive changes in ECG leads II, III, and aVF. This patient
had a hand-sewn LITA graft to the LAD, a hand-sewn SVG
to the first OM, and an MVP SVG to the posterior descend-
ing artery. At the predischarge angiogram a stenosis was
detected in the midsection of the SVG to the OM1 hand-
sewn graft. Though the patient was asymptomatic, a percu-
taneous transluminal coronary angioplasty was performed
in the stenosed graft. The following day, the patient sus-
tained a myocardial infarction. The patient was hemody-
namically stable and did not undergo any further reinter-
vention. This event was not device related.
One patient (3.1%) required prolonged mechanical ven-
tilation due to pneumonia and adult respiratory distress
syndrome. The patient was discharged to rehabilitation for
ventilator weaning.
Other Adverse Events
There were 3 (9.3%) reexplorations for bleeding. One pa-
tient sustained a cardiac tamponade 2 hours after operation
and was returned to the operating room. No source of
bleeding could be identified; there were no anastomotic
TABLE 2. Patient implant characteristics
n  32 MVP study
MVP graft vessel
SVG 23 71.9%
LITA 9 28.1%
MVP target vessel
Mid RCA 1 3.1%
Distal RCA 5 15.6%
Right PDA 1 3.1%
Right PLA 2 6.3%
Mid LAD 7 21.9%
Distal LAD 5 15.6%
1st diagonal 4 12.5%
1st obtuse Marginal 4 12.5%
2nd obtuse Marginal 1 3.1%
Left PLA 1 3.1%
Ramus 1 3.1%
Procedure time (minutes),
range
221 118 (160-840)
CPB time (minutes), range 92 16 (66-124)
Cross clamp time (minutes),*
range
46 19 (23-116)
MVP connection time
(seconds), range
10 6 (2-27)
Total median MVP
deployment and
connection time (seconds)
137 79 (65-370)
MVP, Magnetic Vascular Positioner; SVG, saphenous vein graft; LITA, left
internal thoracic artery; RCA, right coronary artery; PDA, posterior de-
scending artery; PLA, posterolateral artery; LAD, left anterior descending
artery.
*Total crossclamp time for on-pump patients only (n  26).
Figure 2. Postoperative angiogram of MVP anastomosis of a LITA
to LAD graft.
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leaks. One patient was reexplored for bleeding on the ninth
postoperative day. No source of bleeding could be identi-
fied. The third patient experienced bleeding from a side
branch of a radial artery graft leading to a hand-sewn
anastomosis. These 3 patients reached the 30-day clinical
end point and continued to be followed. There were 2
(6.1%) transluminal coronary interventions in this series: 1
patient with an occluded MVP anastomosis and 1 patient
with a stenosed vein graft. Both patients were asymptomatic
and were diagnosed during the routine predischarge angio-
gram. The interventions were performed at the time of the
diagnostic procedure. The patient with the MVP occlusion
was treated by percutaneous stenting of the native coronary
artery (SVG to OM1). The patient with the stenosed hand-
sewn graft had a percutaneous angioplasty procedure to the
graft (SVG to OM1).
There was 1 (3.1%) transient ischemic attack prior to
hospital discharge. The patient’s cerebral computed tomog-
raphy showed no morphologic changes. Recovery was com-
plete.
Intention to Treat
A successful anastomosis was performed in 78% of cases
(32/41). In addition to the 32 patients who received an MVP
anastomosis, 9 patients were classified as intention to treat
patients. Four of the 9 patients initially received the MVP
implant but were converted to a hand-sewn anastomosis for
the following reasons: posterior plaque formation in 1 pa-
tient and 3 patients had inadequate hemostasis at the anas-
tomotic site after the coupling due to insufficient tissue
capture within the magnetic implants. This is an error in
deployment technique and was noted upon immediate test
flushing of the anastomosis. In the other 5 patients the
magnets were not inserted into the coronary artery due to
improper judgment of the target vessel diameter. The target
vessels appeared to be larger from the outside; however,
after incising the vessels, the internal diameter was unac-
ceptable for inserting the magnets due to sclerotic narrow-
ing.
Angiographic Follow-up
A total of 32 patients (32 MVP and 74 hand-sewn grafts)
received the MVP device. Of these, 31 patients (1 death)
had a postoperative coronary angiogram prior to hospital
discharge (mean of 6.3 5.4 days). Thirty-one MVP and 72
hand-sewn anastomoses were evaluated. The overall pa-
tency rate was 93.5% (29 of 31) in the MVP group versus
91.7% (66 of 72) in the hand-sewn group (P  not signif-
icant). In addition to the occluded grafts, 3 hand-sewn grafts
were found to have stenoses 50%. There was a 100% (9
of 9) patency rate in left internal thoracic to LAD MVP
anastomoses.
Thirty-day Clinical Follow-up
There was significant clinical improvement at the 30-day
evaluation with a mean CCS status of 0.37  0.5 at 30 days
postoperatively versus 2.3  0.8 preoperatively (P 
.0001). Angina modification, as assessed by CCS classifi-
cation, measured a secondary efficacy end point. On the
preprocedure evaluation, 81.2% of assessments indicated a
class II or class III angina status, with the remainder falling
into class I or class IV. At the 30-day evaluation 63.3% of
patients were evaluated as class 0 and 36.7% as class I.
No new major adverse events occurred within the 30-day
follow-up period. Minor adverse events included new onset
of atrial fibrillation in 2 patients (6.5%), pneumonia in 1
patient (3.2%), and leg wound infection in 1 patient (3.2%).
The overall minor adverse event rate was 13.1%. Of the 31
surviving patients, ECGs demonstrated no new myocardial
infarction or Q-wave changes during a mean follow-up of
32 days.
Discussion
This study demonstrates the safety and efficacy of a novel,
distal anastomotic connector. In addition, this study repre-
sents the first worldwide clinical use of this unique technol-
ogy in humans. Although several proximal anastomotic
devices have been tested, clinically only a few clinical
studies about devices for the much more technically de-
manding distal anastomosis have been published.7,8 The
authors describe several techniques for performing the anas-
tomoses between SVGs or internal thoracic arteries and
coronary arteries including the use of clips, glue, or stentlike
applicators. The concept of magnetic coupling is vastly
different from other contemplated micromechanical meth-
ods and has several advantages as compared with hand-
sewn anastomosis. It is simple, easy to use, and offers the
benefit of a quick and repeatable anastomosis, which may
facilitate less invasive procedures. The median time for
MVP deployment and connection was 137 seconds. This
included the time to deploy the graft port, the time to deploy
the coronary port, and the time to couple the 2 together. As
each vessel is prepared prior to completion of the anasto-
mosis, the surgeon is able to inspect and confirm a consis-
tent and uniform port opening prior to completing the anas-
tomosis. Although the anastomotic times were very short
with the MVP, it is anticipated that these will be reduced
even further with more frequent use of the device. In 26 of
the 32 patients, an MVP anastomosis was performed on the
arrested heart. This approach was chosen to evaluate the
device while not introducing new variables. However, after
successful application in the stopped heart environment we
also successfully applied the magnetic vascular positioner in
6 beating heart cases. Going forward, we expect that the
MVP will be more widely used in beating heart and less
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invasive approaches as it may limit ischemic times associ-
ated with conventional hand-sewn anastomoses.
There was not an appreciable learning curve associated
with handling of the device. Only a few deployments in the
animal model were needed to become familiar with the
different delivery aspects of the MVP system. An important
part of the MVP procedure is the arteriotomy. A targeted
arteriotomy length of 4.5 to 5.0 mm was desired. There is
approximately 1.0 mm of variability that can be accommo-
dated by the device. No cases had to be aborted due to
improper incision length.
As described in Table 2 the MVP device could be ap-
plied to all 3 coronary arteries and their side branches. Both
LITAs and SVGs were used as bypass conduits for the MVP
anastomosis. The radial artery was not used with the MVP
as the preclinical testing had been done on internal thoracic
arteries and SVGs only. However, the device appears to be
compatible with radial arteries based on our evaluation of
remnant pieces of radial artery during the clinical investi-
gation. Consequently, the MVP system seems to be appli-
cable to all target vessels and graft conduits.
Limitations of Study and Device
This iteration of the device was targeted for coronary ves-
sels with an intraluminal diameter 2.0 mm. Of the vessels
treated with the MVP, 30 were within this range and 2 were
below. At the moment only 1 size magnet is available,
limiting the applicability to target vessels with smaller di-
ameters. A second generation of downsized magnets is
currently being evaluated with early results in animals dem-
onstrating similar patency rates in target vessels as small as
1.5 mm. A device for vessels smaller than 1.0 mm will not
likely be needed due to questionable perfusion benefit as
well as poor patency rates in these coronary targets.12 The
current version of the device with a straight delivery system
limits its flexibility on the posterolateral wall. Even though
an anastomosis could be performed in the circumflex artery
area, an angled delivery system will certainly facilitate
MVP placement in posterolateral vessels. For purposes of
this study, anastomotic target sites with diffuse disease,
calcification, and visible plaques were avoided. However,
we were routinely able to find an acceptable target site. In
cases where an ideal deployment was not achieved (eg, too
much tissue in the lumen), the device could be easily
removed with no apparent trauma to the tissue. Following
removal of the MVP, the device could be redeployed or a
hand-sewn anastomosis could be performed if desired. This
bailout feature helped to provide an extra level of comfort
when performing an anastomosis with a new, mechanical
device.
Angiographic Results
The predischarge angiographic patency of 93.5% for the
MVP system was very encouraging and compares favorably
with other CABG trials with angiographic end points at this
time point.13,14 Of particular note was the 100% patency
rate of the MVP in the LITA-LAD position. In the group of
hand-sewn anastomosis 3 grafts had a stenosis 50%.
These anastomoses were classified as patent in our analysis.
The reason for doing so was that no quantitative coronary
flow analysis was performed and the results could not be
objectively assessed in either group. Due to the radiopacity
of the MVP system, a stenosis in the MVP anastomosis
could not be assessed angiographically, and hence an anas-
tomosis was classified as patent when good runoff could be
demonstrated.
Anticoagulation Regimen
Preoperative antiplatelet therapy was instituted because the
MVP system has exposed foreign material in the blood flow
path. Furthermore, it is yet unknown in humans if the
application of a magnet into the coronary arteries may cause
similar problems as seen after stent application with intimal
hyperplasia formation and restenosis. The combination of
aspirin and clopidogrel was chosen for several reasons.
Clopidogrel, a platelet adenosine diphosphate receptor an-
tagonist, has been shown to inhibit platelet aggregation and
to prevent the recurrence of ischemic events more effec-
tively than aspirin. This is due to a short-lasting metabolite
produced by activation of hepatic cytochrome P450-1A.15
Recent experimental data demonstrated that the antiaggre-
gating, antithrombotic, and antiproliferative activity of clo-
pidogrel was potentiated by aspirin.16 Patients received
preoperative loading dose of clopidogrel and aspirin to
obtain the protective antithrombotic effect immediately at
the end of the operation. Prior to commencing clinical trials
with the MVP system, extensive preclinical testing was
performed. Acute and chronic animal studies (swine and
ovine) were performed to demonstrate acceptable perfor-
mance of the device. In yet unpublished experimental data
a patency rate of 97% after a 1-month follow-up period was
demonstrated using this antiplatelet regimen. Additionally,
animals killed at 3 and 6 months were found to have similar
patency rates and demonstrated a fully healed and stable
tissue layer that lined the lumen and covered the magnets.
Histological analysis showed a smooth, uniform endothelial
covering, lining the entire lumen.17 Hence, we decided to
administer a combination of clopidogrel and aspirin for 12
weeks, and thereafter a single antiplatelet therapy with
aspirin only.
Prior to surgery, many patients are currently taking an-
tiplatelet drugs for various reasons. These include routine
antiplatelet administration following prophylactic loading in
the catheterization laboratory, stent implantation, and clo-
pidogrel therapy for multivessel disease. To minimize
potential thrombotic problems we thought it prudent and
reasonable to use full antiplatelet therapy. Since commence-
Klima et al Evolving Technology
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 5 1573
ET
ment of this trial, recent studies have been published re-
garding reexploration rates in CABG patients on antiplatelet
therapy. Hongo and colleagues18 reported a 6.8% reopera-
tion rate and Yende and colleagues19 reported a rate of
9.8%. We now have additional animal data to support using
reduced antiplatelet dosage in subsequent trials.
Conclusion
This study demonstrates the efficacy and safety of a novel,
distal anastomotic connector by means of magnetic vascular
coupling. The study also represents the first worldwide
clinical application in humans of this new technique. Early
safety and patency of the MVP system appears encouraging.
The device is easy to use and should be adaptable to
OPCAB, MIDCAB, and TECAB procedures. Additional
studies and long-term follow-up will be required to evaluate
the long-term patency of the device.
References
1. Mack MJ, Acuff TE, Casimir-Ahn H, Lo¨nnn UJ, Jansen EW. Video
assisted coronary bypass grafting on the beating heart. Ann Thorac
Surg. 1997;63:S100-3.
2. Scheltes JS, Heikens M, Pistecky PV, van Andel CJ, Borst C. Assess-
ment of patented coronary end-to-side anastomotic devices using mi-
cromechanical bonding. Ann Thorac Surg. 2000;70:218-21.
3. Calafiore AM, Bar-El Y, Vitolla G, et al. Early clinical experience with
a new sutureless anastomotic device for proximal anastomosis of the
saphenous vein to the aorta. J Thorac Cardiovasc Surg. 2001;121:
854-8.
4. Detweiler MB, Detweiler JG, Fenton J. Sutureless and reduced struc-
ture anastomosis of hollow vessels with fibrin glue: a review. J Invest
Surg. 1999;12:245-62.
5. Gundry SR, Black K, Izutani H. Sutureless coronary artery bypass
with biologic glued anastomoses: preliminary in vivo results. J Thorac
Cardiovasc Surg. 2000;120:473-7.
6. Niinami H, Takeuchi Y, Ichiawa S, et al. Coronary artery bypass-
grafting using interrupted anastomosis with the U-clip. Kyobu Geka.
2001;54:1003-6.
7. Tozzi P, Stumpe F, Ruchat O, Marty B, Corno AF, von Segesser LK.
Preliminary clinical experience with the heartflo anastomosis device.
Thorac Cardiovasc Surg. 2001;49:279-82.
8. Eckstein FS, Bonilla LF, Meyer B, Berg TA, Neidhart PP, Schmidli J,
Carrel TP. Sutureless mechanical anastomosis of a saphenous vein
graft to a coronary artery with a new connector. Lancet. 2001;357:
931-2.
9. Falk V, Diegeler A, Walther T, et al. Total endoscopic coronary artery
bypass grafting. Eur J Cardiothorac Surg. 2000;17:38-45.
10. Dogan S, Aybek T, Westphal K, Mierdl S, Moritz A, Wimmer-
Greinecker G. Computer-enhanced totally endoscopic sequential arte-
rial coronary artery bypass. Ann Thorac Surg. 2001;72:610-1.
11. World Medical Association, Inc. The Helsinki Declaration: Ethical
Principles for Medical Research Involving Human Subjects. October
2000 http://www.wma.net/e/policy/17-c_e.html.
12. Paz MA, Lupon J, Bosch X, Pomar JL, Sanz G. Predictors of early
saphenous vein aortocoronary bypass graft occlusion. The GESIC
Study Group. Ann Thorac Surg. 1993;56:1101-6.
13. Okawa Y, Baba H, Hashimoto M, et al. Comparison of standard
coronary artery bypass grafting and minimally invasive direct coronary
artery bypass grafting. Early and mid-term result. Jpn J Thorac Car-
diovasc Surg. 2000;48:725-9.
14. Wiklund L, Johansson M, Bugge M, Radberg LO, Brandup-Wognsen
G, Berglin E. Early outcome and graft patency in mammary artery
grafting of left anterior descending artery with sternotomy or anterior
minithoracotomy. Ann Thorac Surg. 2000;70:79-83.
15. David JL, Limet R. Antiplatelet activity of clopidogrel in coronary
artery bypass graft surgery patients. Thromb Haemost. 1999;82:1417-
21.
16. Herbert JM, Dol F, Bernat A, Falotico R, Lale A, Savi P. The
antiaggregating and antithrombotic activity of clopidogrel is potenti-
ated by aspirin in several experimental models in the rabbit. Thromb
Haemost. 1998;80:512-8.
17. Adams DH, Filsoufi F, Aklog L, et al. Automated distal coronary
bypass using a novel magnetic coupler. American Association for
Thoracic Surgery 82nd Annual Meeting, Washington, DC, May 5-8,
2002, T2 (Abstract): 230.
18. Hongo RH, Ley J, Dick SE, Yee RR. The effect on clopidogrel in
combination with aspirin when given before coronary artery bypass
grafting. J Am Coll Card. 2002;40:231-7.
19. Yende S, Wunderfink RG. Effect of clopidogrel on bleeding after
coronary bypass surgery. Crit Care Med. 2001;29:1271-5.
Evolving Technology Klima et al
1574 The Journal of Thoracic and Cardiovascular Surgery ● November 2003
ET
